NR0B1 and Ewing sarcoma: In summary, although there are currently no drugs able to target DAX-1 and block its function, studies intended to understand its structure, its mechanism of interaction with other transcriptional (co)factors, and the identification of other protein–protein interactions in the Ewing sarcoma context could provide new insights to design new therapeutic molecules (Figure 1).